Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

NCT05592418 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Post COVID-19 Condition
Long COVID

Interventions

DRUG: Rintatolimod
OTHER: Placebo / Normal Saline

Sponsor

AIM ImmunoTech Inc.

Collaborators

[object Object]